The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 02, 2013

Filed:

Oct. 28, 2009
Applicants:

John M. Baust, Owego, NY (US);

John G. Baust, Owego, NY (US);

Anthony T. Robilotto, Binghamton, NY (US);

Kristi K. Snyder, Candor, NY (US);

Robert G. Van Buskirk, Apalachin, NY (US);

Inventors:

John M. Baust, Owego, NY (US);

John G. Baust, Owego, NY (US);

Anthony T. Robilotto, Binghamton, NY (US);

Kristi K. Snyder, Candor, NY (US);

Robert G. Van Buskirk, Apalachin, NY (US);

Assignee:

CPSI Holdings LLC, Owego, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 18/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The resorbable cryoprobe device and process is a novel approach for treating localized disease allowing for the precise combined application of freezing temperatures and cytotoxic or cryosensitizing agents within a self-contained matrix/package for optimized tissue destruction. The cryopellet is comprised of a list of components including a source of cryogen to produce the sub-zero temperatures, a porous matrix to contain the cytotoxic agent, cytotoxic agent, and a delivery packet. Data presented herein demonstrates the efficacy of this approach in destroying cancerous tissue. For example, the application of freezing temperatures to −10° C. results in approximately 15% cell death, while exposure to cytotoxic agents such as TRAIL produces minimal cell death. The utilization of the cryopellet approach results in a synergistic effect yielding complete cell death at the same temperature. The innovation behind the resorbable probe application includes the strategic combination of agents to activate intrinsic or extrinsic cell death responses (including apoptosis and necrosis), unique packaging of the cryogen and cytotoxic agent, and a unique delivery system. The resorbable cryoprobe technology will assist directly in the treatment of cancer, as well as will likely lead to broader application for disease treatment.


Find Patent Forward Citations

Loading…